Mouse study: age-related Lamtor5 decline in macrophages linked to senescence and systemic aging
In mice, the abstract reports that Lamtor5 declines with age in macrophages; removing it made macrophages senescent, and transferring these cells to young mice accelerated aging, while cGAS-targeting approaches reduced aging-associated inflammation in aged mice. [1]
Automatic summary · not editorially reviewed
The key findings
Lamtor5 is described as an age-dependent factor controlling macrophage senescence and peripheral aging in mice. [1]
Delivering senescent Lamtor5-ablating macrophages accelerated aging in young mice, while young macrophages or senolytic elimination corrected aging in myeloid Lamtor5 knockout mice. [1]
A macrophage-targeting cGAS siRNA or a small peptide targeting the Lamtor5/cGAS interface alleviated aging-associated inflammation and tissue dysfunction in aged mice. [1]
The source at a glance
- Study type / format
- Preclinical mouse study (abstract)
- Population / context
- Mice and mouse macrophages, including naturally aging mice, young mice and myeloid Lamtor5 conditional knockout mice
- Summary based on
- Study abstract
- Original publication
- July 16, 2026
Lamtor5 loss in mouse macrophages and senescence
The abstract describes Lamtor5, a late endosomal/lysosomal adapter also called MAPK and mTOR activator 5, as an age-dependent factor controlling macrophage senescence and peripheral aging. Macrophages lacking Lamtor5 showed senescent signatures, metabolic defects and aging-related transcriptomic and epigenetic features, which the authors say matched macrophages from naturally aging mice. This is a comparison of measured features in mouse cells, not evidence about human lifespan.
Supporting source [1]
Transplanted senescent macrophages and young-cell correction in mice
The abstract reports that delivering senescent Lamtor5-ablating macrophages accelerated aging in young mice. Conversely, transplanting young macrophages or senolytically eliminating senescent cells corrected the aging manifestation in mice with a myeloid-specific conditional knockout of Lamtor5. These are experimental interventions in mice; the abstract does not report human data, and the observed associations do not establish that the same interventions would work in people.
Supporting source [1]
cGAS interaction and siRNA or peptide in aged mice
Mechanistically, the abstract states that Lamtor5 physically interacted with cGMP-AMP synthase (cGAS) and promoted its degradation in an ESCRT manner. Applying a macrophage-targeting cGAS small interfering RNA or a small peptide targeting the Lamtor5/cGAS interface profoundly alleviated aging-associated inflammation and tissue dysfunction in aged mice. The abstract frames these findings as opening an avenue for macrophage-based therapeutics; it does not report a tested treatment for people or any clinical outcome.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. All reported experiments involve mice or mouse cells, and the abstract gives no sample sizes, follow-up durations or human data. The proposed macrophage-based therapeutic avenue is not a tested treatment.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lv N, Tang Y, Zhang W, Zhang Q, Zhang H, Gao H, Cui S, Krasny S, Shi L. · europepmc.org · July 16, 2026